Literature DB >> 21850024

Whole-body UVB irradiation during allogeneic hematopoietic cell transplantation is safe and decreases acute graft-versus-host disease.

Marina Kreutz1, Sigrid Karrer, Petra Hoffmann, Eva Gottfried, Rolf-Markus Szeimies, Joachim Hahn, Matthias Edinger, Michael Landthaler, Reinhard Andreesen, Miriam Merad, Ernst Holler.   

Abstract

Depletion of host Langerhans cells (LCs) prevents cutaneous graft-versus-host disease (GvHD) in mice. We analyzed whether UVB irradiation is tolerated during the course of human allogeneic hematopoietic cell transplantation and whether depletion of LCs by broadband UVB could improve GvHD outcome. A total of 17 patients received six whole-body UVB irradiations with 75% of the individually determined minimal erythemal dose after conditioning with a reduced intensity protocol. LCs, dermal dendritic cells (DCs), and macrophages were analyzed before and after UVB irradiation by immunohistochemical analysis. Circulating blood cells and serum factors were analyzed in parallel. In striking contrast to previous data, our irradiation protocol was well tolerated in all patients. UVB treatment decreased the number of LCs and also affected dermal DCs. UVB-treated patients also had significantly higher 25-hydroxyvitamin D3 serum levels and higher numbers of circulating CD4+ FoxP3+ regulatory T cells. Strikingly, nine out of nine patients with complete LC depletion (<1 LC per field) developed only grade I GvHD or no GvHD up to day 100. Our results strongly suggest that prophylactic UVB irradiation post transplant is safe and should be further explored as a clinical strategy to prevent acute (skin) GvHD.

Entities:  

Mesh:

Year:  2011        PMID: 21850024      PMCID: PMC4144809          DOI: 10.1038/jid.2011.255

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  32 in total

1.  Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions.

Authors:  Nadira Durakovic; Karl B Bezak; Mario Skarica; Vedran Radojcic; Ephraim J Fuchs; George F Murphy; Leo Luznik
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

2.  Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes.

Authors:  Shelley Gorman; L Alexandra Kuritzky; Melinda A Judge; Katie M Dixon; Jacqueline P McGlade; Rebecca S Mason; John J Finlay-Jones; Prue H Hart
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

3.  Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic stem cell transplantation outcome.

Authors:  Meltem Yüksel; Elma Baron; Melissa Camouse; Brenda W Cooper; Hillard M Lazarus; Stanton L Gerson; Mary J Laughlin; Kevin D Cooper; Anita Gilliam; Pingfu Fu; Seth Stevens; Omer N Koç
Journal:  Biol Blood Marrow Transplant       Date:  2006-06       Impact factor: 5.742

4.  MC1288, a vitamin D analog, prevents acute graft-versus-host disease in rat bone marrow transplantation.

Authors:  I Pakkala; E Taskinen; S Pakkala; A Räisänen-Sokolowski
Journal:  Bone Marrow Transplant       Date:  2001-04       Impact factor: 5.483

5.  1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells.

Authors:  Giuseppe Penna; Susana Amuchastegui; Nadia Giarratana; Kenn C Daniel; Marisa Vulcano; Silvano Sozzani; Luciano Adorini
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

6.  Langerhans cells are not required for graft-versus-host disease.

Authors:  Hongmei Li; Daniel H Kaplan; Catherine Matte-Martone; Hung Sheng Tan; Srividhya Venkatesan; Kody Johnson; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Blood       Date:  2010-10-13       Impact factor: 22.113

7.  Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies.

Authors:  Reinhard Marks; Karin Potthoff; Joachim Hahn; Gabriele Ihorst; Hartmut Bertz; Alexandros Spyridonidis; Ernst Holler; Jürgen M Finke
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

8.  Effects of 1 alpha,25-dihydroxyvitamin D3 on macrophage colony-stimulating factor production and proliferation of human monocytic cells.

Authors:  M Kaneki; S Inoue; T Hosoi; Y Mizuno; Y Akedo; A Ikegami; T Nakamura; M Shiraki; H Ito; S Suzu
Journal:  Blood       Date:  1994-04-15       Impact factor: 22.113

9.  Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells.

Authors:  Erin Gatza; Clare E Rogers; Shawn G Clouthier; Kathleen P Lowler; Isao Tawara; Chen Liu; Pavan Reddy; James L M Ferrara
Journal:  Blood       Date:  2008-04-14       Impact factor: 22.113

10.  The fate of human Langerhans cells in hematopoietic stem cell transplantation.

Authors:  Matthew P Collin; Derek N J Hart; Graham H Jackson; Gordon Cook; James Cavet; Stephen Mackinnon; Peter G Middleton; Anne M Dickinson
Journal:  J Exp Med       Date:  2006-01-03       Impact factor: 14.307

View more
  9 in total

1.  Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience.

Authors:  L George; D Peter; M Chopra; B George; A Abraham; V Mathews; A Srivastava; S A Pulimood
Journal:  Bone Marrow Transplant       Date:  2016-02-22       Impact factor: 5.483

2.  Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Anna Yasmine Kirkorian; Robert C Hackman; Jeremy Price; Barry E Storer; Brent L Wood; Marylene Leboeuf; Milena Bogunovic; Rainer Storb; Yoshihiro Inamoto; Mary E Flowers; Paul J Martin; Matthew Collin; Miriam Merad
Journal:  Transplantation       Date:  2014-09-15       Impact factor: 4.939

3.  Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+CD25+Foxp3+ regulatory T cells.

Authors:  Satoshi Iyama; Kazuyuki Murase; Tsutomu Sato; Akari Hashimoto; Ayumi Tatekoshi; Hiroto Horiguchi; Yusuke Kamihara; Kaoru Ono; Shohei Kikuchi; Kohichi Takada; Yutaka Kawano; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Masayoshi Kobune; Satoru Mori; Junji Kato; Toshiharu Yamashita; Junji Kato
Journal:  Int J Hematol       Date:  2014-02-21       Impact factor: 2.490

4.  A question of persistence: Langerhans cells and graft-versus-host disease.

Authors:  Matthew Collin; Laura Jardine
Journal:  Exp Dermatol       Date:  2014-04       Impact factor: 3.960

5.  Fibered Confocal Fluorescence Microscopy for the Noninvasive Imaging of Langerhans Cells in Macaques.

Authors:  Biliana Todorova; Nina Salabert; Sabine Tricot; Raphaël Boisgard; Mélanie Rathaux; Roger Le Grand; Catherine Chapon
Journal:  Contrast Media Mol Imaging       Date:  2017-06-07       Impact factor: 3.161

Review 6.  Langerhans Cells-Programmed by the Epidermis.

Authors:  Kalum Clayton; Andres F Vallejo; James Davies; Sofia Sirvent; Marta E Polak
Journal:  Front Immunol       Date:  2017-11-29       Impact factor: 7.561

Review 7.  Evidence-based, Skin-directed Treatments for Cutaneous Chronic Graft-versus-host Disease.

Authors:  Yoo Jung Kim; Gun Ho Lee; Bernice Y Kwong; Kathryn J Martires
Journal:  Cureus       Date:  2019-12-25

8.  Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution.

Authors:  C Hosing; R Bassett; B Dabaja; R Talpur; A Alousi; S Ciurea; U Popat; M Qazilbash; E J Shpall; Y Oki; Y Nieto; C Pinnix; M Fanale; F Maadani; M Donato; R Champlin; M Duvic
Journal:  Ann Oncol       Date:  2015-09-28       Impact factor: 32.976

9.  1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation.

Authors:  Iris M Heid; Marina Kreutz; Katrin Peter; Peter J Siska; Tobias Roider; Carina Matos; Heiko Bruns; Kathrin Renner; Katrin Singer; Daniela Weber; Martina Güllstorf; Nicolaus Kröger; Daniel Wolff; Wolfgang Herr; Francis Ayuk; Ernst Holler; Klaus Stark
Journal:  Bone Marrow Transplant       Date:  2020-08-27       Impact factor: 5.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.